Pharma Mar Valuation Multiples

Pharma Mar Overview

About Pharma Mar

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Founded

1986

HQ

Employees

509

Website

pharmamar.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $250M

EBITDA: $69M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Pharma Mar Financials

Pharma Mar reported last 12-month revenue of $250M and EBITDA of $69M.

In the same LTM period, Pharma Mar generated $238M in gross profit, $69M in EBITDA, and $66M in net income.

Pharma Mar P&L

In the most recent fiscal year, Pharma Mar reported revenue of $254M and EBITDA of $80M.

Pharma Mar expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pharma Mar Stock Performance

Pharma Mar has current market cap of $2B, and enterprise value of $2B.

Pharma Mar's stock price is $96.53.

Pharma Mar Valuation Multiples

Pharma Mar trades at 6.2x EV/Revenue multiple, and 22.2x EV/EBITDA.

Pharma Mar Financial Valuation Multiples

As of March 21, 2026, Pharma Mar has market cap of $2B and EV of $2B.

Equity research analysts estimate Pharma Mar's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pharma Mar has a P/E ratio of 25.1x.

Pharma Mar Margins & Growth Rates

Pharma Mar's revenue in the last 12 month grew by 13%.

Pharma Mar's revenue per employee in the last FY averaged $0.5M.

Pharma Mar's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pharma Mar's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Pharma Mar Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Pharma Mar M&A Activity

Pharma Mar acquired XXX companies to date.

Last acquisition by Pharma Mar was on XXXXXXXX, XXXXX. Pharma Mar acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pharma Mar Investment Activity

Pharma Mar invested in XXX companies to date.

Pharma Mar made its latest investment on XXXXXXXX, XXXXX. Pharma Mar invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).